18F-GP1 Positron Emission Tomography and Bioprosthetic Aortic Valve Thrombus

Bing, Rong; Deutsch, Manfred; Sellers, Stephanie; Corral, Carlos Alcaide; Andrews, Jack; Beek, Edwin Jacques Rudolph van; Bleiziffer, Sabine; Burchert, Wolfgang; Clark, Tim; Dey, Damini; Friedrichs, Kai; Gummert, Jan; Koglin, Norman; Leipsic, Jonathon; Lindner, Oliver; MacAskill, Mark G.; Milting, Hendrik; Pessotto, Renzo; Preuss, R.; Raftis, Jennifer; Rudolph, Tanja K.; Rudolph, Volker; Slomka, Piotr J.; Stephens, Andrew; Tavares, Adriana; Tzolos, Evangelos; Weir, Nick; White, Audrey; Williams, Michelle C.; Zabel, Reinhard; Dweck, Marc R; Hugenberg, Verena; Newby, David E.

doi:10.1016/j.jcmg.2021.11.015

Cited by 15 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have recently demonstrated that all bioprosthetic valves demonstrate increased 18 F-GP1 uptake on their leaflets, suggesting universal platelet activation and thrombus formation following implantation. 5 Intense activity was observed in patients with hypoattenuated leaflet thickening on their computed tomography scan; however, no significant difference in 18 F-GP1 leaflet activity was observed between surgical and transcatheter bioprostheses including in the neosinus. Further studies are required to tease out the pathological role played by thrombus formation in bioprosthetic valve degeneration.…”

Section: Response To Letter To the Editormentioning

confidence: 86%

Response by Kwiecinski et al to Letter Regarding Article, “Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation”

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Response To Letter To the Editormentioning

confidence: 86%

Response by Kwiecinski et al to Letter Regarding Article, “Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation”

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…Indeed, we have previously demonstrated that 18 F-GP1 binding is markedly increased when platelets are activated. (25) In the current study, we have further assessed this tracer for the coronary circulation. First, we used an ex vivo model of deep arterial injury analogous to coronary plaque rupture.…”

Section: Discussionmentioning

confidence: 99%

Noninvasive In Vivo Coronary Artery Thrombus Imaging

Tzolos

Bing

Andrews

et al. 2023

JACC: Cardiovascular Imaging

Self Cite

View full text Add to dashboard Cite

“…Another imaging modality is 18 F-GP1 PET to detect thrombus formation. 18F-GP1 is a novel elarofiban-derived radiotracer that binds to the glycoprotein (GP) IIb/IIIa receptor on activated platelets and may be a valuable tool for the imaging of non-bacterial valve thrombosis 21…”

Section: Diagnostic Imaging For the Detection Of Valvular Diseasementioning

confidence: 99%

Inflammatory and thrombotic valvulopathies in autoimmune disease

Gartshteyn

Bhave

Joseph

et al. 2022

Heart

View full text Add to dashboard Cite

Rheumatologic diseases are characterised by loss of immune tolerance, resulting in systemic inflammation. Inflammation and scarring of the endocardium, which lines the inner surface of the heart chambers and valves, can result in valvular thickening and dysfunction. Estimates of prevalence vary depending on the sensitivity of the screening methodology used and range from 30%–50% in systemic lupus and rheumatoid arthritis to 10%–30% in ankylosing spondylitis. Progression of valve disease is a slow process but can result in haemodynamically significant complications. Thromboembolic complications such as cerebrovascular occlusions pose a serious risk of morbidity. The presence of antiphospholipid antibodies increases the risk of valvular disease and thrombotic complications. Anticoagulation is recommended in the presence of antiphospholipid antibodies, but the guidance on the role of immunosuppressive therapy to treat valvular disease is lacking. Surgical valve therapy may be considered in severe disease, but there is increased risk in patients with an autoimmune disease which includes a higher risk of infection, thromboembolic and bleeding complications, as well as cardiovascular events in the setting of premature atherosclerotic heart disease. Therefore, management should be provided in a multidisciplinary team that includes a rheumatologist, a cardiologist and a cardiothoracic surgeon; medical therapy should be optimised before considering a high-risk valve surgery.

show abstract

18F-GP1 Positron Emission Tomography and Bioprosthetic Aortic Valve Thrombus

Cited by 15 publications

References 25 publications

Response by Kwiecinski et al to Letter Regarding Article, “Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation”

Response by Kwiecinski et al to Letter Regarding Article, “Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation”

Noninvasive In Vivo Coronary Artery Thrombus Imaging

Inflammatory and thrombotic valvulopathies in autoimmune disease

Contact Info

Product

Resources

About